The 34th edition of EY’s Beyond Borders Biotechnology Report provides an in-depth quantitative and qualitative look at the US and European biotechnology industry’s standing within a complex financing, regulatory and fast evolving healthcare environment. Despite a near closure of the IPO window and a difficult venture capital raising landscape following the sugar high during the pandemic, the start-up innovation engine of the pharmaceutical ecosystem continues to produce novel treatments. Biotech’s are advancing novel molecular entities – many enabled by new technologies such as cell and gene therapies, mRNA, Antibody-Drug Conjugates (ADC), CAR-T, while using generative AI/ML to create efficiencies in the process. We will explore these current topics – and more – during the Beyond Borders session.